ALN OATF Vena Cava Filter

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-14

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Migration of a thrombus in the pulmonary circulation is the leading cause of pulmonary embolism (PE). It can be prevented mechanically by implanting a vena cava filter (VCF) in the inferior vena cava. The implation of a VCF is indicated for patients with acute PE and a contraindication to anticoagulation, with an acute deep vein thrombosis (DVT) without PE and a contraindication to anticoagulation or with acute venous thromboembolism (less than 3 months) in whom an interventional gesture at hemorrhagic and thromboembolic risk contraindicates anticoagulation.

The purpose of this study is to describe the rates of implantation, removal and complications associated with the use of the optional ALN OATF VCF in current practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System

NCT02674672

Pulmonary Thrombo-embolism

COMPLETED NA

Predicting the Safety and Effectiveness of Inferior Vena Cava Filters

NCT02381509

Pulmonary Embolism Deep Vein Thrombosis

COMPLETED

Cystic Fibrosis and Totally Implantable Vascular Access Devices

NCT00244270

Cystic Fibrosis Venous Thrombosis

COMPLETED PHASE4

A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System

NCT01305564

Pulmonary Embolism

COMPLETED NA

Crux Biomedical Vena Cava Filter Study - United States

NCT01120509

Pulmonary Embolism

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vena Cava Filter

Participants implanted with the vena cava filter OATF (ALN)

Filter implantation

Intervention Type DEVICE

Implantation of OATF ALN vena cava filter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Filter implantation

Implantation of OATF ALN vena cava filter

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient implanted with an ALN OATF VCF
* Patient informed

Exclusion Criteria

* Minor patient
* Adult patient under a legal protection measure
* Pregnant, parturient or breastfeeding women
* Patient who refused to participate
* Patient who cannot or does not wish to be followed by the Interventional Radiology Department

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No